MADRIGAL PHARMACEUTICALS, INC. (MDGL) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 23.06M; Formula and calculation Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 23.06M | Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 23.06M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-03-31 | 23.06M | (m) | (m) |
| 2025-12-31 | 22.94M | (m) | (m) |
| 2025-09-30 | 22.71M | (m) | (m) |
| 2025-06-30 | 22.29M | (m) | (m) |
| 2025-03-31 | 22.20M | (m) | (m) |
| 2024-09-30 | 21.81M | (m) | (m) |
| 2024-06-30 | 21.71M | (m) | (m) |
| 2024-03-31 | 21.31M | (m) | (m) |
| 2023-09-30 | 19.74M | (m) | (m) |
| 2023-06-30 | 18.47M | (m) | (m) |
| 2023-03-31 | 18.29M | (m) | (m) |
| 2022-12-31 | 18.14M | (m) | (m) |
| 2022-09-30 | 17.10M | (m) | (m) |
| 2022-06-30 | 17.10M | (m) | (m) |
| 2022-03-31 | 17.10M | (m) | (m) |
| 2021-09-30 | 17.10M | (m) | (m) |
| 2021-06-30 | 16.60M | (m) | (m) |
| 2021-03-31 | 16.58M | (m) | (m) |
| 2020-09-30 | 15.47M | (m) | (m) |
| 2020-06-30 | 15.44M | (m) | (m) |
| 2020-03-31 | 15.43M | (m) | (m) |
| 2019-09-30 | 15.43M | (m) | (m) |
| 2019-06-30 | 15.43M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |